Clinical Trial Will Involve 100 individuals in UAE to be Followed by Obtaining Regulatory Approvals and Commercialization
Khalifa University of Science and Technology, along with its business and investment arm Khalifa University Enterprises Company (KUEC), and Advanced Laser Aesthetics (ALA) have signed a tripartite research collaboration agreement to validate L-Nutra’s Diabetes Regression and Remission Program (DRRP) through clinical trials.
The collaboration was announced during the that runs from 15 – 17 April at the Abu Dhabi National Exhibition Center (ADNEC). The agreement signing was attended by Khalifa University President H. E. Professor Ebrahim Al Hajri, H.E. Amal Nasser Al Jaberi, CEO, KUEC, and Dr. Mohamed Kebir, Chairman and CEO, ALA, which is the exclusive distributor of L-Nutra’s DRRP in the region, Dr. Jospeh Antoun Chairman and CEO of L-Nutra, in addition to Dr. Valter Longo, Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California.
The collaboration will facilitate a clinical trial involving 100 individuals in the UAE to validate the efficacy of the DRRP product in managing or reversing Type 2 diabetes, followed by obtaining regulatory approvals and commercialization. The trial will include multi-omics profiling and AI-based data interpretation.
H.E. Amal Nasser Al Jaberi said: “KUEC is delighted to be part of this tripartite agreement that aims to validate L-Nutra’s DRRP and explore the commercialization potential. This technology solution promises to have far-reaching applications in the healthcare sector and as the business and investment arm of Khalifa University, we encourage innovation and inspire new technology startups, motivating researchers, students and alumni to explore entrepreneurship based on university research outputs.”
Professor Habiba Alsafar, Dean, College of Medicine and Health Sciences (CMHS), Khalifa University, said: “This landmark research collaboration agreement for the clinical trial with ALA underscores Khalifa University’s role as a national leader in transformative health research. By combining our research excellence with global innovation in nutrition science, we are proud to drive forward new solutions that align with the UAE’s healthcare priorities and position the University at the forefront of preventive medicine in the region.”
Dr. Mohamed Kebir Chairman and CEO of ALA said: “We are honored to collaborate with Khalifa University and L-Nutra on this pioneering clinical trial that brings science-driven solutions to the forefront of diabetes care in the UAE. This partnership reflects our commitment to transforming the way we approach chronic disease through innovative, non-invasive interventions.”
Dr. Joseph Antoun Chairman and CEO of L-Nutra said: “This collaboration marks a milestone in the global mission to reverse chronic diseases and promote longevity through nutrition-based therapeutics. We are proud to partner with Khalifa University and ALA in advancing the clinical validation of our Diabetes Regression and Remission Program in the UAE.”
This clinical trial represents a major scientific milestone for the UAE, combining cutting-edge nutritional technology with the research leadership of Khalifa University in the fields of biotechnology, precision and preventive medicine, and healthy longevity.
Type 2 diabetes is a key healthcare priority for the UAE, given its potential wide-ranging implications for both population well-being and healthcare resources. Khalifa University is positioned at the forefront of innovation, leading a national effort to explore non-invasive, nutrition-based solutions that can significantly alter the trajectory of chronic disease in the region.
By advancing this clinical trial, Khalifa University, KUEC and ALA are contributing to a global movement that reimagines aging and chronic disease, not as inevitable outcomes but as challenges that science and nutrition can address. The collaboration seeks to advance diabetes care in the UAE through clinical research, regulatory approval, and commercialization of the DRRP product.
